**Investors in Alpha Tau Medical Ltd. (NASDAQ: DRTS) have been greeted with a cautious stance from Piper Sandler analyst Jason Bednar, who assigned a Neutral rating on March 4, 2026. Coupled with a price target of $5, this recommendation signals to investors a need to be vigilant as the stock currently trades at $7.07.**
Market / Price Action
In the latest trading sessions, DRTS has exhibited a modest decline, closing down 4.53% at $7.07, following a decrease of $0.32 per share. The stock traded with some volatility, as indicated by a weekly volatility measure of 11.98%. This recent performance is contrasted starkly against its 52-week range of $244.78 to $7.79, highlighting the significant fluctuations DRTS has faced during the past year. Daily trading volume reached 408,687 shares, slightly above the 374,616 average volume, suggesting a heightened interest amid these price movements. With a market capitalization of approximately $575.53 million and a beta of 1.029, DRTS reflects a moderate level of price sensitivity relative to broader market changes, making it a stock to watch closely for potential spikes or dips.
Short- and Long-Term Performance
Over the past month, DRTS has shown remarkable resilience with a performance increase of 34.3%. This growth momentum extends to the quarterly outlook, where the stock has surged 72.27%. On an annual basis, the stock boasts a solid return of 65.64%, suggesting that despite recent struggles, DRTS has generated favorable performance metrics for savvy investors. This impressive yearly performance is accompanied by a monthly volatility of 7.36%, indicating the stock’s more stable nature in recent times compared to the heightened weekly volatility.
Earnings / Financials
Looking at the most recent earnings report, DRTS posted an earnings per share (EPS) of -$0.11125, marginally surpassing the estimated loss of -$0.12. This represents a surprise factor of -7.29%, indicating that while the company did better than expected in this particular quarter, it still faces challenges in profitability. Interestingly, this marks a slight improvement from the previous quarter’s EPS of -$0.13, which was also aligned with the estimate but achieved a positive surprise of 8.33%. The slight upward trend in earnings performance, even amid losses, could be seen as a positive sign for analysts and investors evaluating longer-term prospects.
Analyst / Consensus View
The consensus on DRTS from analysts reflects a mix of optimism and caution. Piper Sandler’s recent shift to a Neutral rating follows a history of three total ratings, which include two Buy ratings and one Hold. The average price target stands at approximately $8.33, with the highest projection reaching $12 and the lowest aligned with Bednar’s new $5 target. This range indicates a potential upside for investors who believe in the company’s long-term prospects despite the current volatility and the Neutral outlook.
Stock Grading or Fundamental View
According to the Stocks Telegraph Grading Score, Alpha Tau Medical Ltd. holds an ST Score of 40. This score implies a mixed assessment of the company’s financial health and investment potential. The underlying metrics suggest that while there are aspects of innovation and operational capability, there may be underlying weaknesses that warrant the caution reflected in the recent analyst ratings.
Conclusion
For investors considering positioning in Alpha Tau Medical Ltd. (DRTS), this stock presents a hybrid opportunity. It holds potential upside for those who are inclined toward long-term growth investments, especially given its recent performance rebound and positive earnings surprise. However, with the cautious Neutral rating, investors should be prepared for potential risks and market volatility. Careful monitoring of future earnings and broader market conditions will be essential for anyone looking to add DRTS to their portfolio. This stock may appeal to those with a higher risk tolerance, seeking to capitalize on potential market swings within the broader healthcare sector.